AURKA and breast cancer: The drug had a potent inhibitory effect on aurora A kinase (>99%), with a constant of inhibition at 0.116 μM, and a decrease in autophosphorylation of aurora A at the Thr288 site was noted in breast cancer T47D cells exposed to rilpivirine.